Physician profile
David Haffie
NPI 1649252636
$8,986.77
in general payments reported to CMS, 2019-2025
42 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $1,228 · 2021: $1,298 · 2022: $1,429 · 2023: $1,509 · 2024: $1,467 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,954.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,211.62 | 2021-2025 | |
| Novo Nordisk INC | $953.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $899.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $638.98 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.63 | 2019-2025 | Tradjenta, Jardiance |
| Pfizer INC. | $295.98 | 2019-2025 | |
| Allergan, INC. | $289.88 | 2019-2020 | |
| Amarin Pharma, INC. | $217.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $205.85 | 2019-2025 | M-M-R II, Gardasil 9, Capvaxive |
| Amgen INC. | $150.04 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $146.88 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.85 | 2022-2025 | |
| Abbott Laboratories | $141.10 | 2022-2025 | Freestyle Libre 3, Octrode |
| Dexcom, INC. | $133.81 | 2022-2025 | Dexcom G6 Transmitter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haffie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.